A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin (DEFINE)

A Series of Pilot Studies to Evaluate the Haemodynamic and Metabolic Effects of Apelin and Relaxin in Healthy Humans, Subjects With Increased Weight and Patients With Type 2 Diabetes Mellitus

Type two diabetes mellitus (T2DM) is a common, long term metabolic disorder characterised by hyperglycaemia (high blood glucose) resulting from insulin resistance and relative insulin insufficiency. The risk of developing insulin resistance and subsequently T2DM is increased by being overweight and also through a sedentary lifestyle. As the onset can be gradual, physiological damage may have occurred prior to diagnosis. Diabetes is associated with the development of microvascular complications (diabetic nephropathy, neuropathy, and retinopathy), and macrovascular complications (coronary artery disease, peripheral arterial disease, and stroke). While there are many treatments available for T2DM, these complications may still arise, leading to significant morbidity and mortality. There is therefore an urgent need to identify novel signalling pathways that may contribute to the development of diabetes related complications. The identification of these pathways may ultimately lead to the development of new therapies targeting better blood glucose control and preventing these subsequent complications.

Both animal and human studies have indicated that two endogenous peptides, apelin and relaxin both act as vasodilators in the human cardiovascular system and could also have beneficial action in T2DM. Therefore, we aim to carry out experimental medicine studies to test this hypothesis, and explore the signalling pathway in the human vascular system.

Study Overview

• Status: Active, not recruiting
• Conditions: Cardiovascular Diseases; Type 2 Diabetes Mellitus
• Intervention / Treatment: Drug: Apelin; Drug: Normal saline; Drug: Relaxin; Diagnostic test: Verapamil; Diagnostic test: LN Monomethyl arginine

Detailed Description

An extensive body of evidence demonstrates a direct association between T2DM and cardiovascular complications and mortality. Unfortunately, current therapies for diabetes have failed to be translated into improvements in cardiovascular outcomes, highlighting an urgent need to develop novel therapeutic strategies that can ultimately achieve the dual outcome of improving glycaemic control and improving cardiovascular function.

While the precise cellular mechanisms involved remain to be elucidated, we hypothesise that the apelin and relaxin pathways meet these two criteria and therefore are potential therapeutic targets in conditions of abnormal glucose metabolism and heart failure.

Apelin and relaxin are safe for parenteral use as they are naturally occurring peptide hormones, have a short half-life and will be rapidly cleared. They target endogenous receptors and post-receptor signalling, and have been used in human trials without any significant side effects reported.

• Study Type: Interventional
• Enrollment (Estimated): 170
• Phase: Phase 2

Contacts and Locations

Study Locations

• United Kingdom
  • Cambridgeshire
    • Cambridge, Cambridgeshire, United Kingdom, CB20QQ
      • Addenbrooke's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

Healthy participants

• Have given written informed consent to participate
• Aged 18 to 70 years inclusive
• Male or female
• Current non-smoker
• If female, either postmenopausal or on days 2-9 of menstrual cycle and negative pregnancy test performed on the day of the of visit
• BMI in range for studies 1 and 4: 18.5-24.9 kg/m2 with waist circumference lower than 88 centimetres (35 inches) for women or 102 cm (40 inches) for men, and/or body fat level less than 32 % for women or 25% for men
• BMI in range for studies 2 and 3: 18.5-30.0 kg/m2 without limitations in waist circumference or body fat level

Overweight/obese participants

• Have given written informed consent to participate
• Aged 18 to 70 years inclusive
• Male or female
• Current non-smoker
• If female, either postmenopausal or on days 2-9 of menstrual cycle and negative pregnancy test performed on the day of the of visit
• BMI in range of 25-34.9 kg/m2 (inclusive) with either waist circumference higher than 88cm (35 inches) for women or 102 cm (40 inches) for men, and/or body fat levels in excess of 32% for women or 25% for men

Participants with type 2 diabetes mellitus

• Have given written informed consent to participate
• Aged 18 to 70 years inclusive
• Male or female
• Current non-smoker
• If female, either postmenopausal or on days 2-9 of menstrual cycle and negative pregnancy test performed on the day of the of visit
• BMI in range of 25-34.9 kg/m2 (inclusive) with either waist circumference higher than 88cm (35 inches) for women or 102 cm (40 inches) for men, and/or body fat levels in excess of 32% for women or 25% for men
• Documented diagnosis of Type 2 Diabetes Mellitus, either diet controlled or treated with oral hypoglycaemic therapy

Exclusion Criteria:

• Hypersensitivity to any of the study drugs or excipients
• Systemic Hypertension (sustained BP >160/100mmHg) or hypotension (systolic BP below 90 mmHg)
• Known heart disease
• Implanted heart pace-maker or implantable cardioverter defibrillator (ICD)
• Known active malignancy
• Known renal failure (creatinine >140µmol/L)
• Known neurological disease
• History of Scleroderma (Study 4 only)
• Current pregnancy, breast feeding
• Use of vasoactive medications or NSAIDS/aspirin within 24 hours of study visits
• Use of caffeine within 24 hours of study visits
• Current involvement in the active treatment phase of other research studies, (excluding observations/non-interventional)
• Second or third-degree AV block, sino-atrial block, sick sinus syndrome or sinus bradycardia
• Known HIV, hepatitis B or C
• Needle phobia
• Participants treated with formal anticoagulant therapy such as, but not limited to, heparin, warfarin or clopidogrel
• Diagnosis of Type 1 Diabetes Mellitus or current usage of insulin or other injectable drugs for the treatment of diabetes such as but not limited to GLP1 agonists
• BMI <18.5
• Aged <18 or >70 years
• Any other clinical reason which may preclude entry in the opinion of the investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

8

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Substudy 1A - Apelin; In sub-study 1A Healthy participants will receive systemic infusions of Apelin to establish a dose range	Drug: Apelin; Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.
Experimental: Substudy 1B - Apelin/Normal Saline; In sub-study 1B , individuals with Type 2 Diabetes and individuals with increase weight will receive systemic infusions of Apelin or Normal Saline	Drug: Apelin; Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.; Drug: Normal saline; Vehicle; Other Names: Saline
Experimental: Substudy 2A - Relaxin/Normal Saline; In sub-study 2A Healthy participants will receive intra-arterial infusions of Relaxin	Drug: Normal saline; Vehicle; Other Names: Saline; Drug: Relaxin; Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.; Other Names: RLX
Experimental: Substudy 2B - Relaxin; In sub-study 2B Healthy participants will receive intra-arterial infusions of Relaxin followed by verapamil (on a background infusion of either LN Monomethyl Arginine or Normal Saline, to test effects on nitric oxide)	Drug: Relaxin; Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.; Other Names: RLX; Diagnostic test: Verapamil; NO independent challenge agent; Diagnostic test: LN Monomethyl arginine; Basal NO synthase inhibitor; Other Names: LNMMA
Experimental: Substudy 3A - Relaxin with Apelin/Saline; In sub-study 3A Healthy participants will receive intra-arterial infusions of Relaxin (background infusion apelin/Normal Saline)	Drug: Apelin; Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.; Drug: Normal saline; Vehicle; Other Names: Saline; Drug: Relaxin; Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.; Other Names: RLX
Experimental: Substudy 3B - Apelin with Relaxin/Saline; In sub-study 3B Healthy participants will receive intra-arterial infusions of Apelin (background infusion Relaxin/Normal Saline)	Drug: Apelin; Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.; Drug: Normal saline; Vehicle; Other Names: Saline; Drug: Relaxin; Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.; Other Names: RLX
Experimental: Substudy 4 - Apelin and Relaxin; In sub-study 4 Healthy participants, Individuals with Type 2 Diabetes and Individuals with increase weight will receive systemic infusions of Normal saline, Relaxin, Apelin and relaxin	Drug: Apelin; Apelin is an endogenous peptide that activate a single G-protein couple receptor. Apelin inhibits insulin secretion, decreases glucose levels and increases insulin sensitivity.; Drug: Relaxin; Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.; Other Names: RLX
Experimental: Substudy 5 - Relaxin/Saline; In sub-study 5 Healthy participants will be allocated to 1 of 4 Relaxin dosing groups and will receive dorsal hand vein infusion of 3 incremental doses of Normal Saline/ D5W and Relaxin	Drug: Normal saline; Vehicle; Other Names: Saline; Drug: Relaxin; Relaxin is RLN2 encoded endogenous peptide hormone, which binds to G protein coupled receptor RXFP1.; Other Names: RLX

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (Glucose)	Glucose, in mmol/l	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (C-Peptide)	C-peptide, in pmol/L	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (Glucagon)	Glucagon, in pg/ml	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (Insulin)	Insulin, in pmol/L	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1a: Changes in markers of glucose homeostasis in healthy participants after infusion of apelin (TNF-alpha)	TNF-alpha, in pg/ml	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants	Glucose, in mmol/l	Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants	C-peptide, in pmol/L	Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants	Glucagon, in pg/ml	Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants	Insulin, in pmol/L	Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis in participants with increased weight and participants with type 2 diabetes mellitus after infusion of apelin with or without mixed meal tolerance in obese/overweight and T2DM participants	TNF-alpha, in pg/ml	Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 2a: Change in forearm blood flow parameters in healthy participants after infusion of relaxin (Absolute Flow)	Absolute flow in the infused arm, in mg/dL/min	Within visit 2, over a period of up to 4 weeks
Sub-study 2a: Change in forearm blood flow parameters in healthy participants after infusion of relaxin (Percentage Change)	Percentage change in the infused arm, in %	Within visit 2, over a period of up to 4 weeks
Sub-study 2a: Change in forearm blood flow parameters in healthy participants after infusion of relaxin (Ratio)	Ratio, expressed as a number (no units as this is a ratio)	Within visit 2, over a period of up to 4 weeks
Sub-study 2b: Change in forearm blood flow parameters in healthy participants after infusion of relaxin in the presence of L-NMMA or normal saline	Ratio; absolute flow and percentage change in the infused arm	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 2b: Change in forearm blood flow parameters in health participants after infusion of verapamil in the presence of L-NMMA or normal saline (Ratio)	Ratio; expressed as a number (no units as this is a ratio)	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 2b: Change in forearm blood flow parameters in health participants after infusion of verapamil in the presence of L-NMMA or normal saline (Absolute Flow)	Absolute flow in the infused arm, in mg/dL/min	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 2b: Change in forearm blood flow parameters in health participants after infusion of verapamil in the presence of L-NMMA or normal saline (Percentage Change)	Percentage change in the infused arm, In %	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin	Ratio; absolute flow and percentage change in the infused arm	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin (Ratio)	Ratio, expressed as a number (no units as this is a ratio)	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin (Absolute Flow)	Absolute flow in the infused arm, in mg/dL/min	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3a: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial relaxin in the presence of apelin (Percentage Change)	Percentage change in the infused arm, In %	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3b: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial apelin in the presence of relaxin (Ratio)	Ratio, expressed as a number (no units as this is a ratio)	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3b: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial apelin in the presence of relaxin (Absolute Flow)	Absolute flow in the infused arm, in mg/dL/min	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-Study 3b: Change in forearm blood flow parameters in healthy participants after incremental infusions of intra-arterial apelin in the presence of relaxin (Percentage Change)	Percentage change in the infused arm, In %	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin (Glucose)	Glucose, in each of the groups, in mmol/L	Visit 2 to Visit 4, over a period of up to 8 weeks
Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin (C-peptide)	C-peptide, in each of the groups, in pmol/L	Visit 2 to Visit 4, over a period of up to 8 weeks
Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin (Glucagon)	glucagon, in each of the groups,in pg/ml	Visit 2 to Visit 4, over a period of up to 8 weeks
Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin (Insulin)	Insulin, in each of the groups, in pmol/L	Visit 2 to Visit 4, over a period of up to 8 weeks
Sub-study 4: Changes in markers of glucose homeostasis healthy participants, participants with increased weight and participants with type 2 diabetes mellitus after infusion of relaxin with and without apelin (TNF-alpha)	TNF-alpha, in each of the groups, in pg/ml	Visit 2 to Visit 4, over a period of up to 8 weeks
Sub-study 5: Change in hand vein diameter after relaxin infusion in healthy participants	Hand vein Demeter is measured using Aellig dorsal hand vein technique	Visit 2

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Sub-study 1a: Changes in parameters of cardiovascular haemodynamics in healthy participants after infusion of apelin (Echocardiography)	Cardiac output measured by Echocardiography, in L/min	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1a: Changes in parameters of cardiovascular haemodynamics in healthy participants after infusion of apelin (Innocor)	Cardiac output measured by Innocor, in L/min	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1a: Changes in parameters of cardiovascular haemodynamics in healthy participants after infusion of apelin (Bioimpedance)	Cardiac output measured by bioimpedance, in L/min	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin (Echocardiography)	Cardiac output measured by Echocardiography, in L/min	VIsit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin (Innocor)	Cardiac output measured by Innocor, in L/min	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin (Bioimpedance)	Cardiac output measured by bioimpedance, in L/min	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin,after a mixed meal challenge (Echocardiography)	Cardiac output measured by Echocardiography, in L/min	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin, after a mixed meal challenge (Innocor)	Cardiac output measured by Innocor, in L/min	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in parameters of cardiovascular haemodynamics in obese/overweight and T2DM participants after infusion of apelin,after a mixed meal challenge (Bioimpedance)	Cardiac output measured by bioimpedance, in L/min	VIsit 2 to visit 4, over a period of up to 8 weeks
Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (Clugose)	Glucose, in mmol/L	Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (C-peptide)	C-peptide, in pmol/L	Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (Glucagon)	Glucagon, in pg/ml	Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (Insulin)	Insulin, in pmol/L	Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 1b: Changes in markers of glucose homeostasis after infusion of apelin in obese/overweight and T2DM, after a mixed meal challenge (TNF alpha)	TNF alpha, in pg/ml	Visit 2 to visit 5, over a period of up to 14 weeks
Sub-study 2b: Change in forearm blood flow parameters after infusion of verapamil in the presence of L-NMMA or saline (Ratio)	Ratio,expressed as a number (no units as this is a ratio)	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 2b: Change in forearm blood flow parameters after infusion of verapamil in the presence of L-NMMA or saline (Absolute Flow)	Absolute flow in the infused arm, in mg/dL/min	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 2b: Change in forearm blood flow parameters after infusion of verapamil in the presence of L-NMMA or saline (Percentage Change)	Percentage change in the infused arm, In %	Visit 2 to visit 3, over a period of up to 10 weeks
Sub-study 4: Change in cardiovascular haemodynamics after infusion of relaxin (Echocardiography)	Cardiac output measured by Echocardiography, in L/min	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in cardiovascular haemodynamics after infusion of relaxin (Bioimpedance)	Cardiac output measured by bioimpedance, in L/min	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in cardiovascular haemodynamics after infusion of relaxin (Innocor)	Cardiac output measured by Innocor, in L/min	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in cardiovascular haemodynamics after combined infusion of relaxin and apelin (Echocardiography)	Cardiac output measured by Echocardiography, in L/min	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in cardiovascular haemodynamics after combined infusion of relaxin and apelin (Bioimpedance)	Cardiac output measured by bioimpedance, in L/min	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in cardiovascular haemodynamics after combined infusion of relaxin and apelin (Innocor)	Cardiac output measured by Innocor, in L/min	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (Glucose)	Glucose, in mmol/L	Visit 2 to visit 4, over a period of up to 8 weeks
Substudy 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (C-peptide)	C-peptide, in pmol/L	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (Glucagon)	Glucagon, in pg/ml	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (Insulin)	Insulin, in pmol/L	Visit 2 to visit 4, over a period of up to 8 weeks
Sub-study 4: Change in glucose homeostasis after combined infusion of relaxin and apelin (TNF alpha)	TNF alpha, glucose homeostasis	Visit 2 to visit 4, over a period of up to 8 weeks

Collaborators and Investigators

• Sponsor: Cambridge University Hospitals NHS Foundation Trust
• Collaborators: AstraZeneca; University of Cambridge; MedImmune LLC
• Investigators: Principal Investigator: Joseph Cheriyan, MBCHB, FRCP, Cambridge University Hospitals NHS Foundation Trust

Study record dates

Study Major Dates

• Study Start (Actual): March 28, 2018
• Primary Completion (Estimated): September 1, 2025
• Study Completion (Estimated): September 1, 2025

Study Registration Dates

• First Submitted: February 6, 2018
• First Submitted That Met QC Criteria: February 22, 2018
• First Posted (Actual): February 28, 2018

Study Record Updates

• Last Update Posted (Estimated): February 7, 2024
• Last Update Submitted That Met QC Criteria: February 6, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: Apelin; Relaxin
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Arrhythmia Agents; Vasodilator Agents; Enzyme Inhibitors; Membrane Transport Modulators; Calcium-Regulating Hormones and Agents; Calcium Channel Blockers; Verapamil; omega-N-Methylarginine
• Other Study ID Numbers: DEFINE (A094666)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No